Oruka Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Oruka Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- ORKA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0000907654
Board of directors
-
Anders D. Hove · DirectorSince 2024
-
Cameron Turtle · DirectorSince 2024
-
Carl Dambkowski · DirectorSince 2024
-
Christopher Nathan Martin · DirectorSince 2025
-
Daniel J. Mitchell · DirectorSince 2024
-
Jacob Ma-Weaver · DirectorSince 2024
-
James P. Flynn · DirectorSince 2024
-
Kristine M. Ball · DirectorSince 2024
-
Lawrence Otto Klein · Director · Chief Executive OfficerSince 2024
-
Linda Grais · DirectorSince 2024
- Since 2024
-
Raymond L. Woosley · DirectorSince 2024
-
Robert E. Conway · DirectorSince 2024
-
Samarth Kulkarni · DirectorSince 2024
- Since 2024
Chief executives
Lawrence Otto Klein
· President and CEO
Since August 2024
Board connections
8 of this board's directors also sit on 17 other boards.
- via Lawrence Otto Klein, Peter Evan Harwin and Tomas Kiselak
- via Cameron Turtle, Peter Evan Harwin and Tomas Kiselak
- via Peter Evan Harwin and Tomas Kiselak
- via Cameron Turtle and Peter Evan Harwin
- via Peter Evan Harwin and Tomas Kiselak
- via Peter Evan Harwin and Tomas Kiselak
- via Peter Evan Harwin and Tomas Kiselak
- via Peter Evan Harwin and Tomas Kiselak
- via Christopher Nathan Martin
- via Samarth Kulkarni
- via Samarth Kulkarni
- via Peter Evan Harwin
- via Linda Grais
- via Christopher Nathan Martin
- via Linda Grais
- via Lawrence Otto Klein
- via James P. Flynn
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $333,548,062
- 105 sales by 7 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 21, 2026 | Agarwal Arjun Officer (Senior Vice President, Finance) | Open-market sale | −533 | $95.75 | $51,035 |
| Sep 21, 2026 | Quinlan Paul T Officer (General Counsel) | Option exercise | +10,000 | $7.80 | $78,000 |
| Sep 21, 2026 | Quinlan Paul T Officer (General Counsel) | Open-market sale | −2,900 | $92.37 | $267,870 |
| Sep 21, 2026 | Quinlan Paul T Officer (General Counsel) | Open-market sale | −3,832 | $93.32 | $357,592 |
| Sep 21, 2026 | Quinlan Paul T Officer (General Counsel) | Open-market sale | −601 | $94.44 | $56,760 |
| Sep 21, 2026 | Quinlan Paul T Officer (General Counsel) | Open-market sale | −2,667 | $95.31 | $254,196 |
| Sep 15, 2026 | Goncalves Joana Officer (Chief Medical Officer) | Option exercise | +3,500 | $6.84 | $23,940 |
| Sep 15, 2026 | Lawrence Otto Klein Director, Officer (Chief Executive Officer) | Open-market sale | −2,452 | $95.71 | $234,681 |
| Sep 15, 2026 | Sandler Laura Lee Officer (Chief Operating Officer) | Open-market sale | −906 | $95.71 | $86,713 |
| Sep 15, 2026 | Quinlan Paul T Officer (General Counsel) | Open-market sale | −1,039 | $95.71 | $99,443 |
| Sep 15, 2026 | Goncalves Joana Officer (Chief Medical Officer) | Option exercise | +3,500 | $7.80 | $27,300 |
| Sep 15, 2026 | Goncalves Joana Officer (Chief Medical Officer) | Open-market sale | −2,384 | $91.10 | $217,173 |
| Sep 15, 2026 | Goncalves Joana Officer (Chief Medical Officer) | Open-market sale | −3,150 | $92.03 | $289,890 |
| Sep 15, 2026 | Goncalves Joana Officer (Chief Medical Officer) | Open-market sale | −1,366 | $92.99 | $127,023 |
| Sep 15, 2026 | Goncalves Joana Officer (Chief Medical Officer) | Open-market sale | −100 | $94.22 | $9,422 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.